We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
-0.77%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.55B
AUM Growth
-$472M
Cap. Flow
-$301M
Cap. Flow %
-3.99%
Top 10 Hldgs %
20.77%
Holding
863
New
59
Increased
344
Reduced
256
Closed
128

Top Buys

Rank Stock Value
1
NKE icon
Nike
NKE
+$25.4M
2
ABBV icon
AbbVie
ABBV
+$21.9M
3
KYNB
Kyntra Bio
KYNB
+$19.2M
4
WM icon
Waste Management
WM
+$19M
5
GILD icon
Gilead Sciences
GILD
+$17.7M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$70.2M
2
ARRY
Array Biopharma Inc
ARRY
+$45.8M
3
BIIB icon
Biogen
BIIB
+$43.3M
4
META icon
Meta Platforms (Facebook)
META
+$24.8M
5
AMGN icon
Amgen
AMGN
+$21.7M

Sector Composition

Rank Sector Weight
1 Healthcare 31.81%
2 Technology 18.27%
3 Financials 10.05%
4 Consumer Discretionary 9.39%
5 Communication Services 7.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARX
51
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$29M 0.38%
1,228,000
+50,000
+4% +$1.48M
NKE icon
52
Nike
NKE
$61.9B
$27.8M 0.37%
+295,763
New +$25.4M
UNP icon
53
Union Pacific
UNP
$183B
$26.4M 0.35%
163,188
+14,919
+10% +$2.51M
EMR icon
54
Emerson Electric
EMR
$82.9B
$25.6M 0.34%
382,028
+43,374
+13% +$2.73M
TECH icon
55
Bio-Techne
TECH
$11.2B
$25.4M 0.34%
519,428
+87,360
+20% +$4.38M
KEYS icon
56
Keysight
KEYS
$54.5B
$25.4M 0.34%
260,897
-23,892
-8% -$2.21M
ALL icon
57
Allstate
ALL
$66.9B
$25.1M 0.33%
231,247
+37,129
+19% +$3.87M
ISRG icon
58
Intuitive Surgical
ISRG
$121B
$24.4M 0.32%
135,705
+70,497
+108% +$12.2M
BMRN icon
59
BioMarin Pharmaceuticals
BMRN
$11.5B
$24.2M 0.32%
359,520
-86,410
-19% -$6.66M
ADI icon
60
Analog Devices
ADI
$181B
$24M 0.32%
214,821
-19,816
-8% -$2.24M
INTC icon
61
Intel
INTC
$466B
$23.4M 0.31%
454,549
-41,564
-8% -$2.04M
PTCT icon
62
PTC Therapeutics
PTCT
$6.37B
$23.4M 0.31%
690,523
+50,000
+8% +$2.18M
TXN icon
63
Texas Instruments
TXN
$255B
$23.2M 0.31%
179,842
-70,542
-28% -$8.69M
ANSS
64
DELISTED
Ansys
ANSS
$22.9M 0.3%
103,557
+37,901
+58% +$7.98M
BIO icon
65
Bio-Rad Laboratories Class A
BIO
$8.42B
$22.8M 0.3%
68,450
+23,660
+53% +$7.72M
PRU icon
66
Prudential Financial
PRU
$41.7B
– –
-238,677
Closed -$21.6M
ARWR icon
67
Arrowhead Research
ARWR
$12.1B
$22.1M 0.29%
784,000
+255,000
+48% +$7.55M
INCY icon
68
Incyte
INCY
$23.5B
$21.8M 0.29%
294,191
-100,305
-25% -$8.11M
XLRN
69
DELISTED
Acceleron Pharma
XLRN
$21.8M 0.29%
551,500
+169,552
+44% +$7.36M
ONC
70
BeOne Medicines Ltd
ONC
$33.8B
$21.5M 0.29%
175,752
-58,000
-25% -$7.7M
SHW icon
71
Sherwin-Williams
SHW
$78.3B
$21.5M 0.28%
117,138
-47,649
-29% -$8.11M
WBC
72
DELISTED
WABCO HOLDINGS INC.
WBC
$21M 0.28%
157,305
+66,365
+73% +$8.83M
PTC icon
73
PTC
PTC
$13.7B
$20.5M 0.27%
301,153
+73,188
+32% +$5.35M
WFC icon
74
Wells Fargo
WFC
$261B
$20M 0.26%
395,942
+239,386
+153% +$11.3M
SAGE
75
DELISTED
Sage Therapeutics
SAGE
$19.5M 0.26%
139,300
+21,000
+18% +$3.51M
1 2
3
4 5

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q3 2019 Portfolio in Review

As of Q3 2019, Candriam SCA held 863 positions worth $7.55B, down 5.9% from $8.02B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Candriam SCA withdrew a net $301M in Q3 2019, closing 128 positions and reducing 256 holdings. Its most notable exit was Celgene Corp, an estimated $70.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 33% a quarter earlier, followed by Technology and Financials.

Against the trend, Candriam SCA opened a new position in Nike worth $27.8M.

  • Candriam SCA's largest Q3 2019 buy was Nike: 295,763 shares worth $27.8M.
  • Candriam SCA added most to AbbVie in Q3 2019, an estimated $21.9M increase.
  • Candriam SCA's biggest Q3 2019 reduction was Biogen, cutting an estimated $43.3M.
  • Candriam SCA fully exited Celgene Corp in Q3 2019, selling an estimated $70.2M.
  • Candriam SCA's ten largest holdings make up 21% of its $7.55B portfolio in Q3 2019.
  • Candriam SCA opened 59 new positions and closed 128 in Q3 2019.
  • Candriam SCA's portfolio value fell 5.9% quarter-over-quarter to $7.55B.

Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.